Neurogene Inc. logo NGNE - Neurogene Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 5
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $69.00 DETAILS
HIGH: $69.00
LOW: $69.00
MEDIAN: $69.00
CONSENSUS: $69.00
UPSIDE: 149.01%

Stock News

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2026 financial results and highlighted recent corporate updates. “The significant unmet need in Rett syndrome and strong interest among physicians and caregivers continue to drive momentum for NGN-401, with approximately 90% of participants dosed in the Embolden™ registra.

May 12, 2026 12:05 PM • businesswire.com
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting supporting the intracerebroventricular (ICV) route of administration as a routine approach for delivering medicines, including gene therapies, to treat central nervous system (CNS) disorders. The presentation furt.

May 12, 2026 02:00 AM • businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 122,565 shares of the Company's common stock to two new employees (the “Inducement Grants”) on May 5, 2026 (the “Grant Date”), including an.

May 06, 2026 12:01 PM • businesswire.com
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an upcoming poster presentation that will demystify the intracerebroventricular (ICV) route of administration as a well-established, routinely performed neurosurgical procedure and a deliberate delivery strategy designed to maximize efficacy for central nervous system (CNS) gene therap.

Apr 28, 2026 03:30 AM • businesswire.com
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, J.D., to its Board of Directors. Ms. Shafer brings more than 20 years of industry experience building and leading high-performing commercial organizations and launching therapies for.

Apr 20, 2026 03:30 AM • businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 69,140 shares of the Company's common stock to four new employees (the “Inducement Grants”) on April 6, 2026 (the “Grant Date”). The Inducem.

Apr 08, 2026 12:01 PM • businesswire.com
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced full year 2025 financial results and highlighted recent corporate updates. “We continue to demonstrate strong execution, with completion of enrollment in the Embolden registrational trial, dosing more than half of participants, and receipt of Breakthrough Therapy designation for NGN-40.

Mar 24, 2026 03:30 AM • businesswire.com
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference

Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference

Neurogene (NASDAQ: NGNE) CEO and founder Rachel McMinn outlined the company's progress toward a potential commercial launch for its lead gene therapy candidate, NGN-401, during a fireside chat focused on Rett syndrome, regulatory alignment, trial design, and upcoming catalysts. Company focus and lead program McMinn described Neurogene as a genetic medicines company developing treatments for "devastating

Mar 20, 2026 11:02 PM • defenseworld.net
Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the Stifel 2026 Virtual CNS Forum. Format: Management will participate in a fireside chat Date: Wednesday, March 18 at 9:00 a.m. ET A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's webs.

Mar 11, 2026 03:30 AM • businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,450 shares of the Company's common stock to four new employees (the “Inducement Grants”) on March 2, 2026 (the “Grant Date”). The Inducem.

Mar 03, 2026 11:01 AM • businesswire.com
Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More

Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More

Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts' earnings estimates and giving forward guidance above consensus, Nvidia Corp. (NASDAQ: NVDA) initially opened higher amid a rush of retail buying. Still, the... Here Are Friday's Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More.

Feb 27, 2026 02:59 AM • 247wallst.com
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, an investigational gene therapy in late-stage clinical development as a potential best-in-class treatment for Rett syndrome. The Breakthrough Therapy designation was based on the F.

Feb 26, 2026 11:01 AM • businesswire.com
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit

Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit

Neurogene (NASDAQ: NGNE) is advancing a genetic medicines pipeline focused on rare neurologic diseases, with its lead program NGN-401 aimed at treating Rett syndrome, President and CFO Christine Mikail said at Guggenheim's 2026 Emerging Outlook Biotech Summit. Mikail described Rett syndrome as a "devastating neurologic disease" that primarily affects girls. She said children often show developmental

Feb 15, 2026 08:02 PM • defenseworld.net
Neurogene to Participate in Upcoming Investor Conferences

Neurogene to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Guggenheim Emerging Outlook: Biotech Summit 2026 Format: Management will participate in a fireside chat and investor meetings Date: Thursday, February 12 at 9:00 a.m. ET TD Cowen 46th Annual Health Care Conference F.

Feb 05, 2026 02:30 AM • businesswire.com
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company's common stock to one new employee (the “Inducement Grant”) on February 2, 2026 (the “Grant Date”). The Induceme.

Feb 04, 2026 11:01 AM • businesswire.com

Price Targets